Portfolio company Themis Bioscience was acquired by MSD to accelerate coronavirus vaccine development.
Themis Bioscience developed vaccines for infectious diseases using a proprietary measles virus vector-based platform technology
Themis Bioscience developed vaccines for infectious diseases using a proprietary measles virus vector-based platform technology. This innovative approach enabled the creation of immunotherapies for various indications, with their lead product being a vaccine candidate against the tropical disease Chikungunya.